

## Disclosures

### Personal Commercial (5)

| Company Name         | Relationship Category     | Compensation Level | Topic Area(s)                              |
|----------------------|---------------------------|--------------------|--|
| <i>Self</i>          |                           |                    |  |
| Abbott Laboratories  | Consultant Fees/Honoraria | Modest (< \$5,000) | <i>Invasive CV Angio and Interventions</i> |
| Abiomed              | Consultant Fees/Honoraria | Modest (< \$5,000) | <i>Invasive CV Angio and Interventions</i> |
| Abiomed              | Speaker's Bureau          | Modest (< \$5,000) | <i>Invasive CV Angio and Interventions</i> |
| Corvia               | Consultant Fees/Honoraria | Modest (< \$5,000) | <i>Other</i>                               |
| Edwards Lifesciences | Speaker's Bureau          | Modest (< \$5,000) | <i>Valvular Heart Disease</i>              |

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (7)

| Trial Name                                 | Trial Sponsor        | Trial Funding Source |
|--|----------------------|----------------------|
| Triluminate                                | Abbott Laboratories  |                      |
| MitraClip G4 Registry                      | Abbott Laboratories  |                      |
| Restore EF                                 | Abiomed              |                      |
| Reprise IV                                 | Boston Scientific    |                      |
| Mitral contour system for reducing MR      | CARILLON             |                      |
| Reduce LAP                                 | Corvia               |                      |
| P3 mitral valve-in-valve Intermediate risk | Edwards Lifesciences |                      |

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (1)

| Year        | Case Title          | Represented | Description | Compensation       |
|-------------|---------------------|-------------|-------------|--------------------|
| <i>Self</i> |                     |             |             |                    |
| 2019        | Medical malpractice | Defendant   |             | Modest (< \$5,000) |

† Commercial Funding Source | ‡ Trial Name

## Agreement

Certified Education Attestation | Signed on 7/26/2019

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 7/26/2019

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

## On-Going Obligation Agreement | Signed on 5/12/2020

---

### **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.